The analysts forecast global osteoarthritis pain drugs market to grow at a CAGR of 8.38% during the period 2016-2020. The report covers the present scenario and the growth prospects of the global osteoarthritis pain drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat osteoarthritis pain. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market.
The following companies are the key players in the Global Osteoarthritis Pain Drugs Market: Abbott Laboratories, Johnson & Johnson, Novartis International, and Pfizer. Other prominent vendors in the market are: AbbVie, Abiogen Pharma, Afferent Pharmaceuticals, Astellas Pharma, BioDelivery Sciences International, CrystalGenomics, Cytori Therapeutics, Daiichi Sankyo, Eli Lilly, Endo Pharmaceuticals Holdings, Horizon Pharma, iCeutica, Iroko Pharmaceuticals, Merck, Nuvo Research, Regeneron Pharmaceuticals, Sanofi, SantoSolve, Techfields Pharma, Winston Pharmaceuticals, Yooyoung Pharmaceutical, and Zynerba Pharmaceuticals.
Order a copy of report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=582841
According to the osteoarthritis pain drugs market a key driver of market growth is the high numbers of unmet medical needs. There are a number of unmet medical needs in this market due to the chronic nature of osteoarthritis and the absence of curative therapies. With drugs such as NSAID's, simple analgesics, corticosteroids, and opioids proving effective for individuals with early-to-mid stages of osteoarthritis pain, the competition in the market is strong. However, these options do not provide adequate pain relief in the late stages of osteoarthritis. Ultimately, effective treatment of osteoarthritis pain requires an improved anti-inflammatory molecule, which gives reason for R&D to develop new drugs with better MOA and minimal adverse effects. Thus, absence of effective and safe long-term treatment for creates numerous opportunities for pharmaceutical companies.
The global osteoarthritis pain drugs market a key trend that will boost market growth is the emergence of new treatments. Cardax, a development stage life sciences company, is developing astaxanthin therapies for osteoarthritis treatment. The therapy is expected to fulfil large unmet medical needs in the market. Moreover, Arthritis Research UK is conducting studies to develop new treatments for osteoarthritis. One such study is the arcOGEN study, where the genes involved in osteoarthritis are being investigated, and early trials of stem-cell research are done to help in cartilage regrowth.) is the effective solution.
Inquire more about Global Osteoarthritis Pain Drugs Market 2016-2020 report at @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=582841
Global Osteoarthritis Pain Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Osteoarthritis, the most common type of arthritis, is a leading cause of disability. It is a chronic, progressive degenerative joint disease, which is characterized by gradual destruction of the articular cartilage, hypertrophy of the bone margins, and a series of biochemical and morphological changes in the synovial membrane and joint capsule. This results in pain and loss of movement. It is also known as degenerative joint disease, hypertrophic arthritis, and degenerative arthritis, and is most commonly prevalent in older (above 60 years of age) and middle-aged people (between 40-59 years of age). The exact etiology of osteoarthritis is not well understood, but is believed to be an outcome of mechanical and molecular events in the affected joint. Increasing age, obesity, overuse of the joint, weak thigh muscles, and genetics are some of the common risk factors. Treatment is given depending upon the affected joint, including the hand, wrist, neck, back, knee, and hip, and involves medication and exercise.
Further, the report states that one challenge that could restrict market growth is the consumer's preference for alternate therapies.
RnR Market Research
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
RSS / Feeds: http://www.rnrmarketresearch.com/feed
P: + 1 888 391 5441